Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant |
| |
Authors: | Zhiwei Sui Quanjiao Chen Rui Wu Hongbo Zhang Mei Zheng Hanzhong Wang Ze Chen |
| |
Institution: | (1) State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071, Hubei, China;(2) College of Life Sciences, Hunan Normal University, Changsha, 410081, Hunan, China;(3) Shanghai Institute of Biological Products, Shanghai, 200052, China;(4) Graduate University of Chinese Academy of Sciences, Beijing, 100049, China; |
| |
Abstract: | Influenza vaccines based on conserved antigens could provide cross-protection against infections by multiple subtypes of influenza
A virus. Influenza matrix protein 2 (M2) is highly conserved in all influenza A strains. In this study, we deleted the transmembrane
domain of the M2 of the avian influenza virus (AIV) A/Chicken/Jiangsu/7/2002 (H9N2) strain to create an M2 without a transmembrane
domain, named sM2, which was efficiently expressed in Escherichia coli. The sM2 protein was administered intranasally to mice in combination with chitosan adjuvant three times at an interval of
3 weeks. Three weeks after the last immunization, the mice were challenged with a lethal dose (5 × LD50) of A/Chicken/Jiangsu/7/2002 (H9N2) virus, PR8 (H1N1) virus and A/Chicken/Henan/12/2004 (H5N1) virus. The protective immunity
of the vaccine was evaluated by determining the survival rates, residual lung virus titers, body weight, and the serum antibody
titers of the mice. Nasal administration of 15 μg sM2 in combination with chitosan completely protected mice against the homologous
virus and protected 90 and 30% of the mice against the heterologous H1N1 and H5N1 viruses, respectively. The study indicated
that the sM2 protein was a candidate antigen for a broad-spectrum influenza virus vaccine and that the adjuvant chitosan improved
the efficacy of the sM2 vaccine. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|